← Back
Tandem Diabetes Care
TNDM · listed on Nasdaq · worth $1.38 billion
$19.79
+0.56% on Oct 29
No insider bought Tandem Diabetes Care stock in the last year. They sold it 1 time, $32.6K in all. One member of Congress reported trading Tandem Diabetes Care in the last year.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
63.8M shares
92% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider sold Tandem Diabetes Care stock and none bought. Every one of the 1 sale is marked on its filing as planned in advance.
Planned sales
Form 144 notices filed for Tandem Diabetes Care in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Director Christopher J. Twomey filed to sell 1,700 shares on 27 Oct; sold 1,700 by 27 Oct10b5-1 plan adopted 19 May 2026 · Notice on SEC.gov
Executive Mark David Novara filed to sell 360 shares on 17 Sep; no sale reported yet10b5-1 plan adopted 4 Dec 2025 · Notice on SEC.gov
Executive Mark David Novara filed to sell 131 shares on 18 Aug; no sale reported yet10b5-1 plan adopted 4 Dec 2025 · Notice on SEC.gov
US Congress
Members of Congress who reported trading Tandem Diabetes Care in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Tandem Diabetes Care.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 29SoldChristopher J. TwomeyOct 29 · Traded Oct 27 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.1,700 @ $19.15$32.6K
Aug 11, 2025BoughtLeigh VossellerAug 11, 2025 · Traded Aug 8, 2025 · EVP & CHIEF FINANCIAL OFFICER+54%via a trust or family13,720 @ $10.89$149.4K
Analysts, earnings and news
Analysts' price target
$30.52 average
21 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26−$0.30 a share+$0.14
Q4 '25−$0.01 a share+$0.08
Q3 '25−$0.31 a share+$0.03
Q2 '25−$0.48 a share−$0.09